This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.
For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy. * Participants will complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice * Participants between clinic visits, will be asked to complete the oral weekly survey at home via the mobile or web based patient portal. The survey can be completed on a computer, tablet or smartphone at home or on a tablet at the time of scheduled visit. * The first 100 participants to complete the survey will receive a passive care team alert for responses (per DFHCC policy) * The second 100 participants to complete the survey will receive an active care team alert for responses.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
100
2\) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity. Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol. The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher).
Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting "mark as reviewed" button as mandated for all clinical messages within 48 hours per policy.
Dana Farber Cancer Institute
Boston, Massachusetts, United States
ePRO Oral Response Rate
proportion of participants responding to at least 50% of ePRO oral questionnaires at 30 days
Time frame: 30 days
ePRO Oral Response Rate
proportion of participants responding to at least 50% of ePRO oral questionnaires at 60 days
Time frame: 60 days
ePRO Oral Response Rate
proportion of participants responding to at least 50% of ePRO oral questionnaires at 90 days
Time frame: 90 days
Average number of ePRO oral questionnaires completed per week
average number of ePRO oral questionnaires completed per week until discontinuation of OCDT or end of study (whichever occurs first)
Time frame: 90 Days
Proportion of Participants reporting ePRO grade 3+ toxicity
proportion of participants reporting grade 3+ toxicity on at least one ePRO oral questionnaire among participants who responded to at least one ePRO oral questionnaire
Time frame: 90 Days
Proportion of Participants with an ePRO Intervention
proportion of participants who were called by an office practice nurse for toxicity, had an OCDT dose modification, urgent clinic visit, ED visit or unplanned hospitalization among participants who responded to at least one ePRO oral questionnaire
Time frame: 90 Days
Participant Report of OCDT Frequency
proportion of participants who reported missing \>20% of prescribed OCDT doses for reasons other than toxicity on at least one ePRO oral report among participants who responded to at least one ePRO oral questionnaire; measured by participant weekly report of dates and time (AM, PM) of missed doses of the prescribed OCDT regimen
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 90 Days
Participant Report of OCDT Frequency
Among participant who self-reported missing ≥20%/\<20% of prescribed OCDT doses via ePRO oral, the proportion for whom EHR prescriptions also indicated non-adherence/adherence; EHR prescriptions measured by Proportion of Days Covered (PDC) = proportion of days covered by OCDT prescription claims divided by 30 days
Time frame: 30 Days
ePRO oral willingness
proportion of participants reporting that they were willing or very willing to use ePRO oral again in the future among participants who responded to at least one ePRO oral questionnaire
Time frame: 90 Days
ePRO oral ease of use
Proportion of participants reporting that ePRO oral was either easy or very easy to use among participants who responded to at least one ePRO oral questionnaire
Time frame: 90 Days